Thrombosis Research
Volume 121, Issue 2 , Pages 175-181 , 2007

Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome

  • Mika Skeppholm

      Affiliations

    • Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiology, SE-182 88 Stockholm, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 8 6556847.
    • ,
  • N. Håkan Wallén

      Affiliations

    • Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiology, SE-182 88 Stockholm, Sweden
    • ,
  • Karin Malmqvist

      Affiliations

    • Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiology, SE-182 88 Stockholm, Sweden
    • ,
  • Anders Kallner

      Affiliations

    • Department of Clinical Chemistry Karolinska University Hospital, Solna, Sweden
    • ,
  • Jovan P. Antovic

      Affiliations

    • Department of Mol Med and Surgery, Karolinska Institutet, Div of Clin Chem and Blood Coagulation Research, Karolinska University Hospital, Solna, Sweden

Received 8 September 2006 ,Revised 26 March 2007 ,Accepted 27 March 2007.

References 

  1. Antovic JP. Thrombin activatable fibrinolysis inhibitor (TAFI) a link between coagulation and fibrinolysis (review). Clin Lab. 2003;49:475–486
  2. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477–14484
  3. Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000;20:2156–2161
  4. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin-activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855–2859
  5. Eichinger S, Schönauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood. 2004;103:3773–3776
  6. Leebeek FWG, van Goor MPJ, Guimares AHC, Brouwers G-J, deMaat MPM, Dippel DWJ, et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost. 2005;3:2211–2218
  7. Montaner J, Ribo M, Monasterio J, Molina CA, Alvarez-Sabin J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke. 2003;34:1038–1040
  8. Silveira A, Schatterman K, Goossens F, Moor E, Scharpé S, Strömqvist M, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost. 2000;84:364–368
  9. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, et al. Plasma thrombin activatable-fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe. Arterioscler Thromb Vasc Biol. 2002;22:867–873
  10. Juhan-Vague I, Morange PE on behalf of the PRIME Study Group. Very high TAFI antigen levels are associated with a lower hard core coronary events: the PRIME Study. J Thromb Haemost. 2003;1:2243–2244
  11. Brouwers G-J, Leebeek FWG, Tanck MWT, Jukema JW, Kluft C, de Maat MPM. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost. 2003;90:92–100
  12. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557–1563
  13. Guimares AHC, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol. 2004;124:659–665
  14. Verdú J, Pascual M, Benlloch S, Snachez J, Lucas J. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD). Thromb Haemost. 2006;95:585–586
  15. Kaftan O, Balcik OS, Cipil H, Ozet G, Bavbek N, Koşar A, et al. Plasma levels of thrombin-activatable fibrinolysis inhibitor in primary and secondary thrombocytosis. Clin Appl Thromb Hemost. 2005;11:449–454
  16. Schatteman KA, Gossens FJ, Scharpé S, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade in human plasma. Clin Chem. 1999;45:807–813
  17. Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost. 2000;83:902–905
  18. Skeppholm M, Wallén H, Blombäck M, Kallner A. Influence of anticoagulants on the measurements of plasma fibrinogen and CRP concentrations; – should citrate or EDTA be used? Scand J Clin Lab Invest [under revision, April 2007].
  19. Cellai AP, Antonucci E, Liotta AA, Fedi S, Marcucci R, Falciani M, et al. TAFI activity and antigen plasma levels are not increased in acute coronary disease patients admitted to coronary care unit. Thromb Res. 2006;118:495–500

☆ Financial support for this investigation was obtained from the Heart and Lung Foundation Sweden, Stiftelsen Serafimerlasarettet, Karolinska Institutet foundation no. 176.

PII: S0049-3848(07)00123-5

doi: 10.1016/j.thromres.2007.03.021

Thrombosis Research
Volume 121, Issue 2 , Pages 175-181 , 2007

Article Tools

* Image Usage & Resolution